Pfizer-partnered Zentalis woos new CEO, cobbles together $200M

Ready to transform itself into a serious mid- to late-stage cancer player that could take on rivals as big as AstraZeneca, a Pfizer-partnered biotech is embracing some big changes.

Eli Lilly vet Kim Blackwell is succeeding Anthony Sun as CEO of Zentalis. Sun, a former VC at Venrock who co-founded Zentalis in 2015, will remain at the helm of its Asia-focused joint venture, Zentera.